Neurology Advisor Contributing Writer

Results from the ACHIEVE II study were presented at the American Headache Society’s 60th Annual Scientific Meeting.

A phase 3 study examined a low-dose subcutaneous autoinjection of sumatriptan in the acute treatment of migraines with or without aura in adults.

Rimegepant is a safe and efficacious pharmacological treatment of acute migraine in adults.

This Phase III, multicenter, double-blind study sought to explore the effect of fremanezumab on the potential reversion from chronic migraine to episodic migraine.

This randomized, open-label study examined participant reported outcomes, safety, and tolerability of onabotulinumtoxinA and topiramate in adults with chronic migraines.

This retrospective study sought to assess migraine patterns in 69 menopausal women between ages 40 and 60 who were treated at Partners Healthcare Hospitals for concurrent migraine headache.

This cross-sectional, observational study sought to evaluate the accuracy of individuals with headache to appraise the relationship between potential trigger factors and headache events.

Fremanezumab has shown efficacy in safely reducing monthly headache days in individuals with chronic migraine.